This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. EGFR inhibitors embrace KRAS. Nat Biotechnol 26, 839–840 (2008). https://doi.org/10.1038/nbt0808-839
Issue Date:
DOI: https://doi.org/10.1038/nbt0808-839
This article is cited by
-
FDA holds court on post hoc data linking KRAS status to drug response
Nature Biotechnology (2009)
-
Trouble at the office
Nature Biotechnology (2008)